Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Hospitalized patients who had advanced COVID-19 with lung involvement and who received the antiviral agent remdesivir (Gilead Sciences) recovered faster than similar patients who received placebo, according to a preliminary data analysis from a US-led randomized, controlled trial. On the basis of
0 Comments
The ILO estimated that people in informal work have experienced a 60% drop in income in the first month of the coronavirus crisis. Rattanakun Thongbun / EyeEm/Getty Images Some 1.6 billion people in informal work, which is nearly half the global workforce, have become at risk of losing income as a result of the coronavirus
0 Comments
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The broad use of telemedicine has been a bright spot in the COVID-19 response, but the pandemic is also creating significant disruption as some physicians are furloughed and others consider practice changes. A recent survey of physicians conducted by Merritt Hawkins
0 Comments
Ancient Greece has always been an interesting topic to ponder about. Lasting for about 350 years, the ancient Greek civilization was one of the largest and most powerful that the world has ever seen, starting from around 776 BC and ending with the fall of Alexander the Great, per historians. However, although it didn’t last
0 Comments
Print this page DUBLIN and SOUTH SAN FRANCISCO, Calif., April 23, 2020 /PRNewswire/ – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first healthy volunteer has been dosed in a Phase 1 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus
0 Comments
A breakthrough treatment providing a long-term cure for children with peanut allergies may soon be widely available. A clinical trial at the Murdoch Children’s Research Institute in Melbourne showed that an experimental peanut-probiotic treatment led to 82 per cent of children who participated successfully being able to eat peanuts. Four years later, 80 per cent
0 Comments
Got Food Allergies? Add Milk To The Worries For Your Meal by Carmen Heredia Rodriguez: [email protected], @caheredia21, Kaiser Health News (KHN) Since her son Matt was an infant, Lynda Mitchell knew he had a milk allergy. She controlled the symptoms by switching his baby formula. But when he was 1, Halloween proved horrifying. While trick-or-treating in
0 Comments
Treatment for Breast cancer FDA Accepts Genentech’s Biologics License Application for Fixed-Dose Subcutaneous Combination of Perjeta And Herceptin For HER2-Positive Breast Cancer Print this page South San Francisco, CA — February 24, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration
0 Comments
Treatment for Dravet Syndrome Zogenix Announces FDA Extension of Review Period for Fintepla in Dravet Syndrome Print this page EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for
0 Comments
tanezumab Treatment for Osteoarthritis U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis Print this page Monday, March 2, 2020 – Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a
0 Comments
tirbanibulin Treatment for Actinic Keratosis Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis Print this page BUFFALO, N.Y., March 09, 2020 (GLOBE NEWSWIRE) – Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced today
0 Comments
ponesimod Treatment for Multiple Sclerosis Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis Print this page TITUSVILLE, NEW JERSEY, March 18, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced the submission of a New Drug Application (NDA) to the U.S.
0 Comments
tivozanib Treatment for Renal Cell Carcinoma AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 31, 2020– AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
0 Comments
idecabtagene vicleucel Treatment for Multiple Myeloma Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA Print this page March 31, 2020 — PRINCETON, NJ. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the
0 Comments
naxitamab Treatment for Neuroblastoma Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA Print this page NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that
0 Comments
lumasiran Treatment for Primary Hyperoxaluria Type 1 (PH1) Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)– April 07, 2020 — Alnylam Pharmaceuticals,
0 Comments
Print this page April 8, 2020 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAFV600E mutation, as detected by an FDA-approved test, after prior
0 Comments
FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas Print this page 13 April 2020 — AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo
0 Comments
FDA Approves Jelmyto (mitomycin) for Treatment of Low-Grade Upper Tract Urothelial Cancer Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Apr. 15, 2020– UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration (FDA) granted expedited approval for Jelmyto (mitomycin) for pyelocalyceal solution, a first-in-class treatment indicated for adults with low-grade upper tract urothelial cancer
0 Comments
FDA Approves Tukysa (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer Print this page BOTHELL, Wash.–(BUSINESS WIRE) April 17, 2020 — Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to Tukysa™ (tucatinib) tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable
0 Comments
FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma Print this page WILMINGTON, Del.–(BUSINESS WIRE)–Apr. 17, 2020– Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously treated,
0 Comments